Efficacy and Safety of CAR-T Cell Products Axicabtagene Ciloleucel, Tisagenlecleucel, and Lisocabtagene Maraleucel for the Treatment of Hematologic Malignancies: A Systematic Review and Meta-Analysis

Efficacy and Safety of CAR-T Cell Products Axicabtagene Ciloleucel, Tisagenlecleucel, and Lisocabtagene Maraleucel for the Treatment of Hematologic Malignancies: A Systematic Review and Meta-Analysis

BackgroundCurrently, three chimeric antigen receptor (CAR)-T cell products axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel have been approved by the U.S. Food and Drug Administration for the treatment of large B cell lymphoma, which provide a novel and promising choice for pa...

Full description

Bibliographic Details
Main Authors: Jun Meng, XiaoQin Wu, Zhen Sun, RenDe Xun, MengSi Liu, Rui Hu, JianChao Huang
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-07-01
Series:Frontiers in Oncology
Subjects:
chimeric antigen receptor T-cell product
CAR-T cell therapy
immunotherapy
lymphoma
leukemia
hematologic malignancy
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.698607/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.698607/full

Similar Items